LOW FEASIBILITY OF SECOND-LINE CHEMOTHERAPY IN PATIENTS WITH DIABETES MELLITUS IN ADVANCED NON-SMALL CELL LUNG CANCER

被引：0
作者：
Kogure, Yoshihito [1 ]
Hori, Kazumi [1 ]
Funahashi, Yoriko [1 ]
Oka, Saori [1 ]
Tsuboi, Rie [1 ]
Adachi, Takashi [1 ]
Ryuge, Misaki [1 ]
Murata, Naohiko [1 ]
Kitagawa, Chiyoe [1 ]
Oki, Masahide [1 ]
Saka, Hideo [1 ]
机构：
[1] Nagoya Med Ctr, Nagoya, Aichi, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
NSCLC; Chemotherapy; diabetes mellitus;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1182 / S1183
页数：2
相关论文
共 50 条
  • [21] Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer
    Kakolyris, S
    Kouroussis, C
    Souglakos, J
    Agelaki, S
    Kalbakis, K
    Vardakis, N
    Vamvakas, L
    Georgoulias, V
    [J]. LUNG CANCER, 2001, 34 : S71 - S76
  • [22] Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia
    Watanabe, Naohiro
    Niho, Seiji
    Kirita, Keisuke
    Umemura, Shigeki
    Matsumoto, Shingo
    Yoh, Kiyotaka
    Ohmatsu, Hironobu
    Goto, Koichi
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (01) : 69 - 74
  • [23] Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer
    Ceresoli, GL
    Gregorc, V
    Cordio, S
    Bencardino, KB
    Schipani, S
    Cozzarini, C
    Bordonaro, R
    Villa, E
    [J]. LUNG CANCER, 2004, 44 (02) : 231 - 239
  • [24] The Efficacy of Second-Line Osimertinib Plus Bevacizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Ji, W.
    Lu, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S631 - S631
  • [25] An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer
    Scagliotti, G
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (16) : 2855 - 2866
  • [26] Influence of Radiotherapy in Second-Line Treatment with Immunotherapy in Patients with Non-Small Cell Lung Cancer
    Azkona, E.
    Carrera, S.
    Rubio, I.
    Mane, J. M.
    Lacambra, I.
    Sancho, A.
    Novo, E.
    Lopez-Vivanco, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S969 - S969
  • [27] Historical evolution of Second-Line Therapy in Non-Small Cell Lung Cancer
    Lazzari, Chiara
    Bulotta, Alessandra
    Ducceschi, Monika
    Vigano, Maria Grazia
    Brioschi, Elena
    Corti, Francesca
    Gianni, Luca
    Gregorc, Vanesa
    [J]. FRONTIERS IN MEDICINE, 2017, 4
  • [28] Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer
    Imai, Hisao
    Kaira, Kyoichi
    Mori, Keita
    Ono, Akira
    Akamatsu, Hiroaki
    Matsumoto, Shunichi
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Harada, Hideyuki
    Naito, Tateaki
    Murakami, Haruyasu
    Endo, Masahiro
    Nakajima, Takashi
    Yamada, Masanobu
    Takahashi, Toshiaki
    [J]. BMC CANCER, 2015, 15
  • [29] A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced non-small cell lung cancer
    Hu, Wei
    Zhang, Zhiping
    [J]. MEDICAL ONCOLOGY, 2015, 32 (06)
  • [30] A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced non-small cell lung cancer
    Wei Hu
    Zhiping Zhang
    [J]. Medical Oncology, 2015, 32
12345